Abstract:Abstract The recent introduction of new-generation immunoassay methods allows the reliable quantification of structural brain markers in peripheral matrices. Neurofilament light chain (NfL), a neuron-specific cytoskeletal component released in extracellular matrices after neuroaxonal impairment, is considered a promising blood marker of active brain pathology. Given its sensitivity to a wide range of neuropathological alterations, NfL has been suggested for the use in clinical practice as a highly sensitive, but unspecific tool to quantify active brain pathology. While large efforts have been put in characterizing its clinical profile in many neurological conditions, NfL has received far less attention as a potential biomarker in major psychiatric disorders. Therefore, we briefly introduce NfL as a marker of neuroaxonal injury, systematically review recent findings on cerebrospinal fluid and blood NfL levels in patients with primary psychiatric conditions and highlight the opportunities and pitfalls. Current evidence suggests an elevation of blood NfL levels in patients with major depression, bipolar disorder, psychotic disorders, anorexia nervosa, and substance use disorders compared to physiological states. However, blood NfL levels strongly vary across diagnostic entities, clinical stage, and patient subgroups, and are influenced by several demographic, clinical, and analytical factors, which require accurate characterization. Potential clinical applications of NfL measure in psychiatry are seen in diagnostic and prognostic algorithms, to exclude neurodegenerative disease, in the assessment of brain toxicity for different pharmacological compounds, and in the longitudinal monitoring of treatment response. The high inter-individual variability of NfL levels and the lack of neurobiological understanding of its release are some of the main current limitations. Overall, this primer aims to introduce researchers and clinicians to NfL measure in the psychiatric field and to provide a conceptual framework for future research directions.

Neurofilament light chain as a promising biomarker for depression diagnosis: a systematic review and meta-analysis

Neurofilament light chain plasma levels in major depressive disorder: a brief research report

Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls

Neurofilament Light Chain As a Potential Biomarker in Plasma for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and a Meta-Analysis.

Association between serum neurofilament light chains and depression: A cross-sectional study based on NHANES 2013–2014 database

Plasma neurofilament light chain levels are associated with depressive and anxiety symptoms in Parkinson’s disease

Serum neurofilament light chain levels are associated with depression among US adults: a cross-sectional analysis among US adults, 2013–2014

Plasma and CSF neurofilament light chain distinguish neurodegenerative from primary psychiatric conditions in a clinical setting

A multicentre validation study of the diagnostic value of plasma neurofilament light

Neurofilament light and glial fibrillary acidic protein in mood and anxiety disorders: A systematic review and meta-analysis

Plasma neurofilament light chain in relation to 10-year change in cognition and neuroimaging markers: a population-based study

Relationship between serum neurofilament light chain protein and depression: A nationwide survey and Mendelian randomization study

Association between serum neurofilament light chains (sNfL) and neurologic disorders in a representative sample of US adults: a cross-sectional study

Elevated plasma neurofilament light was associated with multi-modal neuroimaging features in Alzheimer's disease signature regions and predicted future tau deposition

Elevated Plasma Neurofilament Light Was Associated with Multi-Modal Neuroimaging Features in Alzheimer’s Disease Signature Regions and Predicted Future Tau Deposition

Plasma neurofilament light chain as prognostic marker of cognitive decline in neurodegenerative diseases, a clinical setting study

Neurofilament light chain as a biomarker in neurological disorders

Prognostic performance of blood neurofilament light chain protein in hospitalized COVID-19 patients without major central nervous system manifestations: an individual participant data meta-analysis

Plasma glial fibrillary acidic protein and neurofilament light chain in behavioural variant frontotemporal dementia and primary psychiatric disorders

Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment

Elevated neurofilament light chain in plasma is associated with reduced right hippocampal and amygdala volume in Alzheimer's patients